Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Phase 2 N=38 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Phase 4 N=49 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Phase 2 N=62 Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
Non Small Cell Lung Cancer
Primary: Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response) — 28.6 percentage of participants
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 2 N=75 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Lung Cancer
Primary: Overall Survival at 12 Months — 57 percentage of participants
Phase 2 N=101 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
Phase 2 N=331 Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Lung Cancer · Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung
Primary: Immune-related Progression-free Survival (irPFS) in Participants With Nonsmall-cell Lung Cancer (NSCLC) Per Immune-related Response Criteria (irRC) — 5.52; 5.68; 4.63…
Phase 2 N=51 Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=75 Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
Lung Cancer
Primary: Number of Participants Who Completed Four Cycles of the Carboplatin/Docetaxel Regimen — 57 Participants
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Phase 4 N=109 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods — 5.6 months
Phase 2 N=84 S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
Lung Cancer
Primary: Overall Survival — 21 months
Phase 2 N=19 Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Toxic Death Rate — NA Participants
Phase 2 N=59 S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Lung Cancer
Primary: Selection of One of Two Treatment Regimens (Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel) for Further Study in a Phase III Trial, Based on Median…
Phase 2 N=9 Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
Lung Cancer
Primary: Objective Response Rate (ORR), Presented in Numbers of Participants — 0; 0; 1; 1 Participants
Phase 2 N=48 Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
Lung Cancer · Non-small Cell Lung Cancer (NSCLC)
Primary: Progression-free Survival (PFS) — 8.7 months
Phase 2 N=43 Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Time to Progression-Free Survival (PFS) — 7.9 months
Phase 1 N=11 Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 3; 0 Participants
Phase 2 N=31 Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Number of Subjects With Major Pathologic Response (MPR) — 17 Participants
Phase 3 N=260 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
N/A N=12 Study of Tarceva and Targretin in Stage I-II Lung Cancer
Carcinoma, Non-small-cell Lung
Primary: Number of Participants With Change in Expression Level of EGFR. — 3; 7 Participants
Phase 2 N=9 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I) — 150 mg daily
Phase 2 N=82 Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 2 N=63 Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Three-dimensional Conformal Radiation Therapy (3DRT), in Terms of Gy Per Fraction, Combined With Concurrent Chemotherapy — 0; 1 units on…
Phase 2 N=140 Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Progression Free Survival — 3.4; 4.2; 4.0 months